CGEM
Overvalued by 91.9% based on the discounted cash flow analysis.
Market cap | $829.01 Million |
---|---|
Enterprise Value | - |
Dividend Yield | $0.0 (0.0%) |
Earnings per Share | $0.0 |
Beta | 0.0 |
Outstanding Shares | 43,065,645 |
Avg 30 Day Volume | 725,563 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | 0.0 |
---|---|
PEG | - |
Price to Sales | - |
Price to Book Ratio | - |
Enterprise Value to Revenue | - |
Enterprise Value to EBIT | - |
Enterprise Value to Net Income | - |
Total Debt to Enterprise | - |
Debt to Equity | - |
No data
No data
Cullinan Management is a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients. The Company’s strategy is to build a pi...